Live symbol workspace

CTMX market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $4.40

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$4.18

Resistance

$4.62

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$4.40

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

— 0.0 pts vs previous week

Avg confidence across 2 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

CTMX News Intelligence (1 articles)

AI-curated news influencing CTMX price, sentiment, and trend

Explore All CTMX News with AI Analysis

Economy

2 months, 3 weeks ago

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.

Impact on CTMX: The positive Phase 1 data for CytomX Therapeutics' colorectal cancer treatment leads …

CytomX Therapeutics' stock surges after releasing positive Phase 1 colorectal cancer data, despite weak quarterly … High (80%)

View full analysis →

Yahoo Finance 80% confidence